|
2021 Journal Article Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer stagingChikatamarla, Venkata Avinash, Okano, Satomi, Jenvey, Peter, Ansaldo, Alexander, Roberts, Matthew J., Ramsay, Stuart C., Thomas, Paul A. and Pattison, David A. (2021). Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. EJNMMI Research, 11 (1) 128, 128. doi: 10.1186/s13550-021-00869-5 |
|
2021 Journal Article The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre studyEmmett, Louise, Buteau, James, Papa, Nathan, Moon, Daniel, Thompson, James, Roberts, Matthew J., Rasiah, Kris, Pattison, David A., Yaxley, John, Thomas, Paul, Hutton, Anthony C., Agrawal, Shikha, Amin, Amer, Blazevski, Alexandar, Chalasani, Venu, Ho, Bao, Nguyen, Andrew, Liu, Victor, Lee, Jonathan, Sheehan-Dare, Gemma, Kooner, Raji, Coughlin, Geoff, Chan, Lyn, Cusick, Thomas, Namdarian, Benjamin, Kapoor, Jada, Alghazo, Omar, Woo, Henry H., Lawrentschuk, Nathan ... Stricker, Phillip (2021). The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. European Urology, 80 (6), 682-689. doi: 10.1016/j.eururo.2021.08.002 |
|
2021 Journal Article Major-element geochemistry of pelitesForshaw, Jacob B. and Pattison, David R. M. (2021). Major-element geochemistry of pelites. Geology, 51 (1), 39-43. doi: 10.1130/G50542.1 |
|
2021 Journal Article Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemiaKalff, Victor, Iravani, Amir, Ackhurst, Timothy, Pattison, David A., Eu, Peter, Hofman, Michael S. and Hicks, Rodney J. (2021). Utility of 68Ga-DOTA-Exendin-4 PET/CT imaging in distinguishing between insulinoma and nesidioblastosis in patients with confirmed endogenous hyperinsulinaemic hypoglycaemia. Internal Medicine Journal, 51 (10) imj.15141, 1657-1664. doi: 10.1111/imj.15141 |
|
2021 Journal Article Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRIArnfield, Evyn and Pattison, David A (2021). Identification of Isolated Hepatic Sarcoidosis With 18F-FDG PET/CT and MRI. Clinical Nuclear Medicine, 46 (9), e448-e450. doi: 10.1097/rlu.0000000000003613 |
|
2021 Journal Article Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic reviewMcGeorge, Stephen, Kwok, Michael, Jiang, Andrew, Emmett, Louise, Pattison, David A., Thomas, Paul A., Yaxley, John W. and Roberts, Matthew J. (2021). Dual-tracer positron-emission tomography using prostate-specific membrane antigen and fluorodeoxyglucose for staging of prostate cancer: a systematic review. Advances in Urology, 2021 1544208, 1544208. doi: 10.1155/2021/1544208 |
|
2021 Conference Publication 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer CenterNalder, Mark, Ladwa, Rahul, Raina, Anant, Burge, Matthew E., Love, Amanda, Pattison, David A., Ramsay, Stuart and Wyld, David (2021). 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT) in patients with somatostatin-expressing neuroendocrine tumors: a real-world retrospective review of efficacy and safety from an Australian tertiary cancer Center. 2021 ASCO Annual Meeting I, Virtual, 4-8 June 2021. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2021.39.15_suppl.e16198 |
|
2021 Journal Article UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol)Dhiantravan, Nattakorn, Emmett, Louise, Joshua, Anthony M., Pattison, David A., Francis, Roslyn J., Williams, Scott, Sandhu, Shahneen, Davis, Ian D., Vela, Ian, Neha, Nitika, Bressel, Mathias, Murphy, Declan G., Hofman, Michael S. and Azad, Arun A. (2021). UpFrontPSMA: a randomized phase 2 study of sequential 177Lu-PSMA-617 and docetaxel vs docetaxel in metastatic hormone-naive prostate cancer (clinical trial protocol). BJU International, 128 (3) bju.15384, 331-342. doi: 10.1111/bju.15384 |
|
2021 Journal Article 124I-PET/CT-guided diagnosis and personalized treatment of metastatic papillary thyroid cancer to the pancreasWong, Bernadette Z Y, Dickie, Graeme, Garcia, Peter, Scott, Dominique and Pattison, David A. (2021). 124I-PET/CT-guided diagnosis and personalized treatment of metastatic papillary thyroid cancer to the pancreas. Clinical Nuclear Medicine, 46 (4), 337-339. doi: 10.1097/rlu.0000000000003499 |
|
2021 Conference Publication UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC)Azad, Arun, Dhiantravan, Nattakorn, Emmett, Louise, Joshua, Anthony M., Vela, Ian, Pattison, David A., Francis, Roslyn J., Williams, Scott, Sandhu, Shahneen Kaur, Davis, Ian D., Neha, Nitika, Bressel, Mathias, Murphy, Declan G. and Hofman, Michael S. (2021). UpFrontPSMA: A randomized phase II study of sequential 177Lu-PSMA617 and docetaxel versus docetaxel in metastatic hormone-naive prostate cancer (mHNPC). ASCO Genitourinary Cancers Symposium (GU ASCO), Electr Network, Feb 11-13, 2021. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS. doi: 10.1200/JCO.2021.39.6_suppl.TPS180 |
|
2021 Conference Publication 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603)Hofman, Michael S., Emmett, Louise, Sandhu, Shahneen Kaur, Iravani, Amir, Joshua, Anthony M., Goh, Jeffrey C., Pattison, David A., Tan, Thean Hsiang, Kirkwood, Ian D., Ng, Siobhan, Francis, Roslyn J., Gedye, Craig, Rutherford, Natalie K., Zhang, Alison Yan, McJannett, Margaret Mary, Stockler, Martin R., Violet, John A., Williams, Scott, Martin, Andrew James and Davis, Ian D. (2021). 177Lu-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel: Updated results including progression-free survival (PFS) and patient-reported outcomes (PROs) (TheraP ANZUP 1603). ASCO Genitourinary Cancers Symposium (GU ASCO), Online, 11-13 February 2021. Alexandria, VA, United States: American Society of Clinical Oncology. doi: 10.1200/JCO.2021.39.6_suppl.6 |
|
2021 Journal Article Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarkerChan, David L., Ulaner, Gary A., Pattison, David A., Wyld, David, Ladwa, Rahul, Kirchner, Julian, Li, Bob T, Lai, W Victoria, Pavlakis, Nick, Roach, Paul J and Bailey, Dale L (2021). Dual Positron Emission Tomography imaging in bronchial neuroendocrine neoplasms (NENs): the NETPET score as a prognostic biomarker. Journal of Nuclear Medicine, 62 (9), 1278-1284. doi: 10.2967/jnumed.120.257659 |
|
2021 Journal Article Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2)Roberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2021). Correction to: 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 48, 2, (477-482), 10.1007/s00259-020-04944-2). European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04983-9 |
|
2021 Journal Article Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y)Pattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Correction to: Prospective intra‑individual blinded comparison of [18F]PSMA‑1007 and [68 Ga]Ga‑PSMA‑11 PET/CT imaging in patients with confirmed prostate cancer (European Journal of Nuclear Medicine and Molecular Imaging, (2021), 10.1007/s00259-021-05520-y). European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 789-789. doi: 10.1007/s00259-021-05548-0 |
|
2021 Journal Article Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancerPattison, David A., Debowski, Maciej, Gulhane, Brook, Arnfield, Evyn G., Pelecanos, Anita M., Garcia, Peter L., Latter, Melissa J., Lin, Charles Y., Roberts, Matthew J., Ramsay, Stuart C. and Thomas, Paul A. (2021). Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 49 (2), 763-776. doi: 10.1007/s00259-021-05520-y |
|
2020 Journal Article Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case reportDhanani, Jayesh, Pattison, David A., Burge, Matthew, Williams, Julian, Riedel, Bernhard, Hicks, Rodney J. and Reade, Michael C. (2020). Octreotide for resuscitation of cardiac arrest due to carcinoid crisis precipitated by novel peptide receptor radionuclide therapy (PRRT): A case report. Journal of Critical Care, 60, 319-322. doi: 10.1016/j.jcrc.2020.08.011 |
|
2020 Journal Article The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CTDudoignon, David, Pattison, David A., Legallois, Damien, Hicks, Rodney J. and Aide, Nicolas (2020). The utility of pharmacological and radiological interventions to optimize diagnostic information from PET/CT. Cancer Imaging, 20 (1) 68, 1-12. doi: 10.1186/s40644-020-00344-9 |
|
Featured 2020 Journal Article 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancerRoberts, Matthew J., Morton, Andrew, Donato, Peter, Kyle, Samuel, Pattison, David A., Thomas, Paul, Coughlin, Geoff, Esler, Rachel, Dunglison, Nigel, Gardiner, Robert A., Doi, Suhail A., Emmett, Louise and Yaxley, John (2020). 68Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48 (2), 655-656. doi: 10.1007/s00259-020-04944-2 |
|
2020 Journal Article Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancerViolet, John, Sandhu, Shahneen, Iravani, Amir, Ferdinandus, Justin, Sue-Ping Thang, , Kong, Grace, Kumar, Aravind Ravi, Akhurst, Tim, Pattison, David, Beaulieu, Alexis, Mooi, Jennifer, Tran, Ben, Guo, Christina, Kalff, Victor, Murphy, Declan G., Jackson, Price, Eu, Peter, Scalzo, Mark, Williams, Scott G., Hicks, Rod J., Hofman, Michael S. and Tran, Ben (2020). Long-term follow-up and outcomes of retreatment in an expanded 50-patient single-center phase II prospective trial of 177Lu-PSMA-617 theranostics in metastatic castration-resistant prostate cancer. Journal of Nuclear Medicine, 61 (6), 857-865. doi: 10.2967/jnumed.119.236414 |
|
2020 Journal Article Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate CancerViolet, J., Sandhu, S., Iravani, A., Ferdinandus, J., Thang, S. P., Kong, G., Kumar, A. Ravi, Akhurst, T., Pattison, D. A., Beaulieu, A., Mooi, J., Guo, C., Kalff, V., Murphy, D. G., Jackson, P., Eu, P., Scalzo, M., Williams, S., Hicks, R. J. and Hofman, M. S. (2020). Re: Long Term Follow-Up and Outcomes of Re-Treatment in an Expanded 50 Patient Single-Center Phase II Prospective Trial of Lutetium-177 (177Lu) PSMA-617 Theranostics in Metastatic Castrate-Resistant Prostate Cancer. Journal of Urology, 203 (5). doi: 10.1097/JU.0000000000000779.01 |
